The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Large Volume Wearable Injectors Market (3rd Edition), 2017-2027

  • Lowest Price Guaranteed From USD 2,499

  • Published
    January 2017

  • Pages
    365

  • View Count
    2471

Example Insights

An updated edition is available at the following link 

View 4th edition

  1. There are over 50 different large volume wearable injectors (including variants) that are either commercialized or are under development. Of these, around 60% are for delivery of insulin and the rest are for delivery of other biologics. Of the devices being developed for delivery of non-insulin biologics, two devices are approved by the USFDA. These include the SmartDose Electronic Wearable Injector (by West Pharmaceutical Services) approved for the delivery of Repatha and OnProTM (using the OmniPod device, by Amgen and Insulet Corporation). OnProTM was initially developed by Insulet as an insulin delivery device and it was later positioned to administer Neulasta.
  2. There are several other known references of drug-device combinations that are being evaluated in clinical studies; examples include SteadyMed Therapeutics’ PatchPump (with Treprostinil and Ketorolac), NeuroDerm’s CRONO ND (with NDO612 and NDO712), Roche’s Single-use injection device (with Herceptin) and scPharmaceuticals’s scWear Infusor (with Ceftriaxone and Furosemide).
  3. The commercially available insulin-based large volume wearable injectors can accommodate volumes of up to 5 ml. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, with improved design, several devices with capacity of holding up to 20 ml drug are being developed for delivery of biologics. In fact, over 50% of the devices that we identified for administration of non-insulin biologics have the capability of carrying 5-20 ml drug while 35% of these devices can hold over 20 ml drug.
  4. Our analysis suggests that close to 100 biologics (marketed / under development) are suited for delivery via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. These biologics (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems. We believe that some of these drugs, if tested and approved with large volume wearable injectors, are likely to make a substantial contribution to the market’s evolution in the mid-long term.
  5. Innovation in the field is primarily being driven by start-ups / small companies; examples of firms working for delivery of non-insulin biologics include (in alphabetical order) Elcam Drug Delivery Systems, Enable Injections, NeuroDerm, scPharmaceuticals, Sensile Medical. Notable examples of start-ups that have taken initiatives for delivery of insulin include Cellnovo, CeQur, Debiotech, PicoSulin, SOOIL and ViCentra. In addition, a number of large companies are making notable contribution in this field; prominent players include Becton Dickinson, Johnson & Johnson, Medtronic, Roche and West Pharmaceutical Services.
  6. Several other companies engaged in this domain have reported positive clinical outcomes of their drug-device combinations. scPharmaceuticals is expecting the commercial launch of its two product candidates for the drugs furosemide and cephalosporin in 2017 / 18. In addition, Neuroderm and SteadyMed Therapeutics are also hopeful of making their products commercially available in the near future. At the same time, insulin delivery devices, such as OmniPod, are now also being explored for the delivery of non-insulin drugs, such as the gonadotropin-releasing hormone developed by Ferring Pharmaceuticals.
  7. The overall market for large volume wearable injectors is likely to grow at an aggressive rate of over 150%. We believe that OmniPod will continue to lead the market for insulin delivery. However, majority of the growth is likely to come from drug-device combinations under trials for non-insulin biologics. In our base scenario, we have predicted that the annual sales volume of such devices could be over 40 million units by 2027.

Overview

Drug delivery systems optimized to provide flexibility in dosing regimen, reduce the number of hospital visits, decrease dependence on healthcare professionals and enhance adherence to the therapeutic regimen have become the preferred choice of drug administration. The large scale adoption of prefilled syringes, the first ready-to-use injection device to be marketed, demonstrated the growing interest in the concept of such convenient drug delivery systems. In addition, several pen-injectors and autoinjectors have witnessed an impressive growth in the recent past. However, these hand-held devices are only capable of administering drugs with dosing volume close to 1 ml. With over 900 biologics being developed (most of these are highly viscous and are required to be delivered in volumes greater than 1 ml), there is a growing demand for self-administration devices than can overcome this unmet need.

Large volume wearable injectors, an advanced version of the existing self-injection devices, are expected to gather interest from a wide customer base. In fact, there are a number of such injectors commercially available for delivery of insulin. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, it is worth highlighting that till date only a few large volume wearable injectors (for instance, Amgen . Insulet Corporation's OnProTM and West Pharmaceutical's SmartDose Electronic Wearable Injector) have been approved for the administration of a non-insulin biologic. Despite the uncertainties related to the device development and approval, many companies are investing their time, money and resources to develop these novel devices. In addition to the publically known programs, pharma companies have many undisclosed programs that are likely to provide the necessary growth impetus in the long term.

It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million. The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.

Several partnerships have also been inked in this domain in the last few years. Most of these are focused on the development / commercialization of a variety of wearable injectors. Such partnerships are important for technological integration, supply of devices and also facilitate the conduct of clinical trials related to drug-device combination products. We believe that the device developers will continue to strive to introduce unique and user-friendly features into their proprietary range of devices. The upgradation of existing devices to more competent / next generation devices will serve as a key driver of immediate near-term growth.

 

Scope of the Report

The Large Volume Wearable Injectors Market (3rd Edition), 2017-2027 report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace. In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs / therapies. This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.

It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US. However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.

One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms. Amongst other elements, the report elaborates on the following areas:

  • An overview of the current market landscape in terms of the key players involved, development status of pipeline products (marketed / under development), type of dose (bolus / continuous / both), usability (disposable / reusable) and key indications.
  • Detailed profiles of large volume wearable devices that are being developed for the delivery of biologics (including insulin), highlighting their key features, current status of development, recent developments and associated collaborations.
  • An exhaustive review of over 300 biologics, which are potential candidates for delivery using large volume wearable injectors. The molecules / therapies have been categorized into most-likely, likely and less-likely candidates for administration using large volume wearable injectors. This categorization is based on various parameters including recommended volume, route of administration, frequency of the dose, standard / weight based dose and the chronicity of target indication.
  • Comprehensive case studies on drugs that are being evaluated for delivery via large volume wearable injectors, highlighting their specifications, mechanisms of action, current status of development, sales, respective dosages and any other recent developments.
  • An illustrative grid representation of the devices based on the category of device (insulin / non-insulin biologic), type of dose and type of device (infusion pump / patch pump). In addition, the report includes an insightful 2 X 2 matrix analysis, highlighting the positioning of the devices based on product competitiveness and supplier power.
  • A discussion on the key drivers and challenges, in terms of the strengths, weaknesses, opportunities and threats (SWOT), which are likely to impact the future growth of this upcoming area.

The study provides a detailed market forecast and opportunity analysis for the period between 2017 and 2027. The research, analysis and insights presented in this report include potential sales of the drug-device combinations that are being evaluated and are anticipated to enter the market in the next few years. To add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios. It is worth noting that, although the market of insulin delivery devices is relatively more mature, we have included a high-level opportunity analysis on the large volume wearable injectors being developed for delivery of insulin as well.

Our opinions and insights presented in this study were influenced by discussions conducted with several experts in this area. Specifically, we solicited the opinions of senior representatives including Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the large volume wearable injectors market.

Chapter 3  provides a general introduction to the market and highlights the growing demand for self-administration injection devices. The chapter lays emphasis on the need for such devices driven by the rising incidence of chronic diseases and emergency cases reported per day. Subsequently, it covers the different types of self-injection devices available in the market, highlighting their advantages. This section also features a brief discussion on the concerns related to needlestick injuries and emphasizes the growing preference for safe and easy-to-use devices.

Chapter 4  presents two separate lists of the large volume wearable injectors for insulin and the other biologics. In addition, the chapter includes a detailed analysis of both these lists based on the products’ status of development, device category (infusion pump / patch pump), type of dose (bolus / continuous) and the capacity of each device. Specifically for insulin delivery devices, we have identified whether the device is equipped with continuous glucose monitoring (CGM) monitoring or not.

Chapter 5  presents key takeaways from the market landscape of this emerging field. It features a comparison of product competitiveness and supplier power of each device in the form of a 2 x 2 matrix. In addition, the chapter includes a grid based representation of devices based on the target indication, status of development, type of dose (continuous / bolus / both) and type of device (patch pump / infusion pump). The chapter also provides an analysis of the patents granted / filed in this space over the last three years.

Chapter 6  presents detailed profiles on the large volume wearable injectors being developed for biologics / drugs other than insulin. The profiles include information about the developer of the device, device specifications and features, advantages, current status of development and related collaborations. We have presented such insights on 10 devices capable of delivering large dosage volumes.

Chapter 7  is focused on the devices developed / being developed for the administration of insulin. It presents information on diabetes, the most popular target indication, including information on its epidemiology and the evolution of insulin-delivery systems. Additionally, it includes detailed profiles on some of the large volume wearable devices developed / being developed for the delivery of insulin. Each profile covers information on the device developer, device specifications, advantages and the associated developments. The chapter also includes a social media analysis highlighting the popularity of these devices in the industry.

Chapter 8  provides detailed case studies on the drugs / therapies that are currently being evaluated with the devices mentioned in chapter 4. Each case study includes drug / therapy specifications, respective mechanisms of action, current status of development, information on the sales of each product, dosage and recent developments.

Chapter 9  presents a list of candidates (marketed / pipeline) that have the potential to be administered using large volume wearable injectors in the future. The likelihood of delivery of a molecule was estimated based on the volume of dose, mode of administration, frequency of administration, standard / weight-based dose and the chronicity of the target indication. 

Chapter 10  provides projections of the future opportunity of the large volume wearable injectors market for biologics till 2027. It highlights the market size of such injectors (in terms of value) and the number of units that are likely to be sold within the forecast time period. We have clearly laid out the forecast methodology along with the key assumptions that were taken into consideration for estimating the market size.

Chapter 11  includes comprehensive profiles of the key companies that are active in this market. We have profiled companies ( presented in an alphabetical order ) developing devices for administration of insulin / other biologics. Each company profile includes a company overview, details on its financial performance, product portfolio and collaborations.

Chapter 12  provides a SWOT analysis, highlighting strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 13  summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of large volume wearable injectors market based on the research and analysis described in the previous chapters.

Chapter 14  is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 16  is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Devices
3.3. Self-Administration: An Emerging Trend
3.3.1. Rising Burden of Chronic Diseases
3.3.2. Need for Immediate Treatment in Emergency Situations
3.3.3. Expansion of Injectable Biologics Pipeline
3.3.4. Systems Available for Self-administration
3.3.4.1. Prefilled Syringes
3.3.4.2. Pen-Injectors
3.3.4.3. Autoinjectors
3.3.4.4. Needle-Free Injectors
3.3.4.5. Large Volume Wearable Injectors
3.3.5. Needlestick Injuries
3.3.5.1. Incidence and Cost Burden
3.3.5.2. Prevention of Needlestick Injuries
3.3.5.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Advantages and Future Prospects of Self-Injection Systems
 
4. LARGE VOLUME WEARABLE INJECTORS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Development Landscape
 
4.3. Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
4.3.1. Distribution by Stage of Development
4.3.2. Distribution by Storage Capacity
4.3.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
4.3.4. Distribution by Type of Dose (Bolus / Continuous)
4.3.5. Distribution by Usability (Disposable / Reusable)
4.3.6. Distribution by Leading Players
 
4.4. Large Volume Wearable Injectors: Development Landscape for Insulin
4.4.1. Distribution by Stage of Development
4.4.2. Distribution by Device Volume
4.4.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
4.4.4. Distribution by Usability (Disposable / Reusable)
4.4.5. Distribution by Availability of CGM System
4.4.6. Distribution by Leading Players
 
4.5. Large Volume Wearable Injectors: Distribution by Geography
 
5. PRODUCT COMPETITIVENESS, CLINICAL DESIGN AND PATENT ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis
5.2.1. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
5.2.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
5.3. Grid Analysis: Distribution of Large Volume Wearable Injectors Based on Development Phase and Type of Dosage
5.4. Patent Analysis: Large Volume Wearable Injectors, 2013-2016
5.4.1. Distribution by Current Status
5.4.2. Distribution by Year
5.4.3. Distribution by Key Players
5.4.4. Distribution by Regional Approving Authorities
5.4.5. Distribution by the Type of Patent
5.4.6. Distribution by Patent Expiry Year
 
6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN BIOLOGICS: DEVICE PROFILES
6.1. Chapter Overview
6.2. eLVD Patch Pump (Elcam Drug Delivery Devices (E3D))
6.2.1. Introduction
6.2.2. Product Description
6.2.3. Advantages
 
6.3. Enable Injector (Enable Injections)
6.3.1. Introduction
6.3.2. Product Description
6.3.3. Usage
6.3.4. Advantages
6.3.5. Recent Developments
 
6.4. Lapas (Bespak)
6.4.1. Introduction
6.4.2. Product Description
6.4.3. Advantages
 
6.5. BD Libertas™ Wearable Injector (Becton Dickinson)
6.5.1. Introduction
6.5.2. Product Description
6.5.3. Usage
6.5.4. Advantages
 
6.6. PatchPump (SteadyMed Therapeutics)
6.6.1. Introduction
6.6.2. Product Description
6.6.3. Usage
6.6.4. Advantages
6.6.5. Recent Developments
 
6.7. Precision-Therapy™ Wearable Injector, Flex-Therapy™ Wearable Injector and Flex-Therapy™ Mini Wearable Injector (Unilife Corporation)
6.7.1. Introduction
6.7.2. Product Description
6.7.3. Usage
6.7.4. Advantages
6.7.5. Recent Developments
 
6.8. sc2™Wear Infusor (scPharmaceuticals)
6.8.1. Introduction
6.8.2. Product Description
6.8.3. Advantages
6.8.4. Recent Developments
 
6.9. Single-use Injection Device (Roche)
6.9.1. Introduction
6.9.2. Product Description
6.9.3. Usage
6.9.4. Advantages
6.9.5. Recent Developments
 
6.10. SenseBolus, SensePatch and SenseTrial (Sensile Medical)
6.10.1. Introduction
6.10.2. Product Description
6.10.3. Usage
6.10.4. Advantages
6.10.5. Recent Developments
 
6.11. SmartDose Electronic Wearable Injector (West Pharmaceutical Services)
6.11.1. Introduction
6.11.2. Product Description
6.11.3. Usage
6.11.4. Advantages
6.11.5. Recent Developments
 
7. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN: DEVICE PROFILES
7.1. Chapter Overview
7.2. Diabetes: An Introduction
7.2.1. Epidemiology
7.2.2. Available Therapies
7.2.3. Need for Diabetes Management Systems
7.3. Advanced Insulin Delivery Systems: Device Profiles
 
7.3.1. ACCU-CHEK (Roche Diagnostics)
7.3.1.1. Introduction
7.3.1.2. Product Information
7.3.1.3. Advantages
7.3.1.4. Recent Developments
 
7.3.2. DANA Diabecare Insulin Pumps (SOOIL)
7.3.2.1. Introduction
7.3.2.2. Product Information
7.3.2.3. Advantages
 
7.3.3. JewelPUMP™ I and JewelPUMP™ II (Debiotech)
7.3.3.1. Introduction
7.3.3.2. Product Information
7.3.3.3. Advantages
7.3.3.4. Recent Developments
 
7.3.4. MiniMed 530G (Medtronic)
7.3.4.1. Introduction
7.3.4.2. Product Information
7.3.4.3. Advantages
7.3.4.4. Recent Developments
 
7.3.5. mylife™ YpsoPump (Ypsomed)
7.3.5.1. Introduction
7.3.5.2. Product Information
7.3.5.3. Advantages
 
7.3.6. OmniPod (Insulet Corporation)
7.3.6.1. Introduction
7.3.6.2. Product Information
7.3.6.3. Advantages
7.3.6.4. Recent Developments
 
7.3.7. OneTouch Via™ (Johnson & Johnson)
7.3.7.1. Introduction
7.3.7.2. Product Information
7.3.7.3. Usage
7.3.7.4. Advantages
 
7.3.8. PAQ™ (CeQur)
7.3.8.1. Introduction
7.3.8.2. Product Information
7.3.8.3. Usage
7.3.8.4. Advantages
7.3.8.5. Recent Developments
 
7.3.9. t:flex (Tandem Diabetes Care)
7.3.9.1. Introduction
7.3.9.2. Product Information
7.3.9.3. Advantages
7.3.9.4. Recent Developments
 
7.4. Large Volume Wearable Injectors for Insulin: Trends on Social Media
7.4.1. Large Volume Wearable Injectors for Insulin: Twitter Trends
7.4.2. Large Volume Wearable Injectors for Insulin: Device Recalls
7.4.3. Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
 
8. CASE STUDIES: DRUG-DEVICE COMBINATIONS UNDER EVALUATION
8.1. Chapter Overview
 
8.2. Repatha / Evolocumab / AMG 145
8.2.1. Drug Specifications
8.2.2. Mechanism of Action
8.2.3. Development History
8.2.4. Current Status of Development
8.2.5. Dosage and Sales Information
 
8.3. Treprostinil
8.3.1. Drug Specifications
8.3.2. Mechanism of Action
8.3.3. Development History
8.3.4. Current Status of Development
8.3.5. Dosage and Sales Information
 
8.4. Furosemide
8.4.1. Drug Specifications
8.4.2. Mechanism of Action
8.4.3. Development History
8.4.4. Current Status of Development
8.4.5. Dosage and Sales Information
 
8.5. Herceptin
8.5.1. Drug Specifications
8.5.2. Mechanism of Action
8.5.3. Development History
8.5.4. Current Status of Development
8.5.5. Dosage and Sales Information
 
8.6. ND0612 / Levadopa and Carbidopa
8.6.1. Drug Specifications
8.6.2. Mechanism of Action
8.6.3. Development History
8.6.4. Current Status of Development
8.6.5. Dosage and Sales Information
 
8.7. ND0701 / Apomorphine
8.7.1. Drug Specifications
8.7.2. Mechanism of Action
8.7.3. Current Status of Development
8.7.4. Dosage and Sales Information
 
8.8. SMT-201 / Ketorolac
8.8.1. Drug Specifications
8.8.2. Mechanism of Action
8.8.3. Development History
8.8.4. Current Status of Development
8.8.5. Dosage and Sales Information
 
8.9. Ceftriaxone
8.9.1. Drug Specifications
8.9.2. Mechanism of Action
8.9.3. Development History
8.9.4. Current Status of Development
8.9.5. Dosage and Sales Information
 
9. TARGET BIOLOGICS FOR LARGE VOLUME WEARABLE INJECTORS
9.1. Chapter Overview
9.2. Marketed Biologics
9.2.1. Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
9.2.2. Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
9.2.3. Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
9.3. Pipeline Molecules
9.3.1. Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
9.3.2. Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
9.3.3. Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
 
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Key Assumptions
10.4. Forecast Output
10.4.1. Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2017-2027
10.4.2. Large Volume Wearable Injectors Market for Insulin, 2017-2027
 
11. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS
11.1. Chapter Overview
11.2. Becton Dickinson
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Collaborations
11.2.5. Future Outlook
 
11.3. CeQur
11.3.1. Company Overview
11.3.2. Product Portfolio
11.3.3. Future Outlook
 
11.4. Debiotech
11.4.1. Company Overview
11.4.2. Product Portfolio
11.4.3. Collaborations
11.4.4. Future Outlook
 
11.5. Insulet Corporation
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Product Portfolio
11.5.4. Collaborations
11.5.5. Future Outlook
11.6. Roche Laboratories
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.6.4. Collaborations
11.6.5. Future Outlook
 
11.7. Sensile Medical
11.7.1. Company Overview
11.7.2. Product Portfolio
11.7.3. Collaborations
11.7.4. Future Outlook
 
11.8. SteadyMed Therapeutics
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.8.4. Collaborations
11.8.5. Future Outlook
 
11.9. Tandem Diabetes Care
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Collaborations
11.9.5. Future Outlook
 
11.10. Unilife Corporation
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Product Portfolio
11.10.4. Collaborations
11.10.5. Future Outlook
 
11.11. West Pharmaceutical Services
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Product Portfolio
11.11.4. Collaborations
11.11.5. Future Outlook
 
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
 
13. CONCLUSION
13.1. Novel Drug / Therapy Delivery Solutions Offer a number of Advantages, including Self-Administration in the Home-care Setting
13.2. Technical Improvements have Led to the Development of Advanced Large Volume Wearable Delivery Systems Having Multiple Useful Features
13.3. The Market, Characterized by the Presence of both Large and Small Companies, is Likely to be Impacted by the Growth of the Biologics Market
13.4. Partnerships and Venture Capital Financing have Emerged as Key Drivers of Growth in this Upcoming Area
13.5. The Large Volume Wearable Injector Market is Projected to Grow at an Aggressive Pace Over the Next Decade
13.6. Concluding Remarks
 
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Menachem Zucker, VP and Chief Scientist, Elcam Medical
14.3. Michael Hooven, CEO, Enable Injections
14.4. Ben Moga, President, Ratio Drug Delivery
14.5. Pieter Muntendam, President and CEO, scPharmaceuticals
14.6. Graham Reynolds, VP & GM, Global Biologics and Tiffany H. Burke, Director, Global Communications, West Pharmaceutical Services
 
15.  APPENDIX 1: TABULATED DATA
 
16.  APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Types of Drug Delivery Systems
Figure 3.2  Types of Self-Injection Devices
Figure 3.3  Worldwide Evolution in Healthcare Safety Legislation
Figure 4.1  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Figure 4.2  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Figure 4.3  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Figure 4.4  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
Figure 4.5  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
Figure 4.6  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
Figure 4.7  Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Figure 4.8  Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
Figure 4.9  Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Figure 4.10  Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
Figure 4.11  Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Figure 4.12  Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
Figure 4.13  Large Volume Wearable Injectors: Distribution by Geography
Figure 4.14  Large Volume Wearable Injectors: Regional Landscape
Figure 5.1  Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
Figure 5.2  Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
Figure 5.3  Grid Analysis: Distribution by Stage of Development and Type of Dosage
Figure 5.4  Patent Analysis: Distribution by Current Status
Figure 5.5  Patent Analysis: Distribution by Year
Figure 5.6  Patent Analysis: Distribution by Key Players 
Figure 5.7  Patent Analysis: Distribution by Regional Approving Authorities 
Figure 5.8  Patent Analysis: Distribution by the Type of Patent
Figure 5.9  Patent Analysis: Distribution by Patent Expiry Year 
Figure 7.1  Diabetes: Worldwide Distribution of the Patients (2015)
Figure 7.2  Prevalence of Diabetes: Distribution by Continent (In Million)
Figure 7.3  Insulin-Based Therapies for Diabetes
Figure 7.4  Non-Insulin Therapies for Diabetes
Figure 7.5  Large Volume Wearable Injectors for Insulin: Twitter Trends (2010-2015)
Figure 7.6  Large Volume Wearable Injectors for Insulin: Twitter Word Cloud (2010-2015)
Figure 7.7  Large Volume Wearable Injectors for Insulin: Device Recalls (2010-2015)
Figure 7.8  Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
Figure 8.1  Treprostinil IV Formulation: Annual Sales 2012 - Q1-Q3 2016 (USD Million)
Figure 8.2  Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
Figure 8.3  Herceptin®: Annual Sales, 1999-2015 (CHF Million)
Figure 8.4  Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
Figure 8.5  Apokyn®: Annual Sales, 2011-2015 (USD Million)
Figure 8.6  Rocephin®: Annual Sales, 2014-2015 (CHF Million)
Figure 9.1 Marketed / Under Development Molecules: Parameters and Scoring Criteria
Figure 10.1  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
Figure 10.2  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
Figure 10.3  Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
Figure 10.4  Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
Figure 10.5  Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
Figure 10.6  Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
Figure 11.1  Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
Figure 11.2  Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
Figure 11.3  Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
Figure 11.4  Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
Figure 11.5  Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million) 
Figure 11.6  Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
Figure 11.7  West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
Figure 13.1  Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)

List of Tables

Table 3.1  List of Prefilled Syringes
Table 3.2  List of Pen-Injector Systems
Table 3.3  List of Autoinjector Systems
Table 3.4  List of Needle-Free Injectors
Table 4.1  Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
Table 4.2  Large Volume Wearable Injectors: Development Landscape for Insulin
Table 6.1  Large Volume Wearable Injectors for Non-Insulin Biologics: List of Devices Profiles
Table 7.1  Advanced Insulin Delivery Systems
Table 7.2  DANA Diabecare®: Specifications
Table 7.3  JewelPUMP™: Specifications
Table 7.4  JewelPUMP™: Advantages
Table 7.5  MiniMed® 530G: Specifications
Table 7.6 mylife™ YpsoPump®: Specifications
Table 7.7  OmniPod®: Specifications
Table 7.8  t:flex®: Specifications
Table 8.1  Large Volume Wearable Injectors: Drugs under Evaluation
Table 8.2  Repatha®: Clinical Trials
Table 8.3  Remodulin®: Dosage Regimen
Table 8.4  Orenitram®: Dosage
Table 8.5  Tyvaso®: Dosage
Table 8.6  Furosemide: Clinical Trials
Table 8.7  Furosemide: Manufacturers and Suppliers
Table 8.8  Subcutaneous Herceptin®: Clinical Trials
Table 8.9  ND0612: Clinical Trials
Table 8.10  ND0612H: Phase II Trials (Objectives and Results)
Table 8.11  Levodopa / Carbidopa: Manufacturer and Suppliers
Table 8.12  Ketorolac Tromethamine: Manufacturers and Suppliers
Table 9.1  Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.2  Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.3  Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.4  Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.5  Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.6  Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
Table 10.1  Large Volume Wearable Injectors for Non-Insulin Biologics (Approved / Under Development)
Table 11.1  Large Volume Wearable Injectors: Key Players
Table 11.2  Becton Dickinson: Medical Devices Portfolio
Table 11.3  Debiotech: Medical Devices Portfolio
Table 11.4  Sensile Medical: Medical Devices Portfolio
Table 11.5  SteadyMed Therapeutics: Medical Devices Portfolio
Table 11.6  t:slim X2™ Insulin Pump: Features
Table 11.7  t:slim X2™ Insulin Pump: Technical Specifications
Table 11.8  t:flex® Insulin Pump: Features
Table 11.9  t:flex® Insulin Pump: Technical Specifications
Table 11.10 West Pharmaceutical Services: Medical Devices Portfolio
Table 12.1  Large Volume Wearable Injectors: SWOT Analysis
Table 12.2  Recall of Device (Autoinjectors and Prefilled Syringes)
Table 15.1  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Table 15.2  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Table 15.3  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Table 15.4  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
Table 15.5  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
Table 15.6  Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
Table 15.7  Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Table 15.8  Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
Table 15.9  Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Table 15.10  Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
Table 15.11  Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Table 15.12  Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
Table 15.13  Large Volume Wearable Injectors: Distribution by Geography
Table 15.14  List of Patents, 2013-2016
Table 15.15  Patent Analysis: Distribution by Current Status
Table 15.16  Patent Analysis: Distribution by Year
Table 15.17  Patent Analysis: Distribution by Key Players
Table 15.18  Patent Analysis: Distribution by Regional Approving Authorities
Table 15.19  Patent Analysis: Distribution by the Type of Patent
Table 15.20 Patent Analysis: Distribution by Patent Expiry Year
Table 15.21  Diabetes: Worldwide Distribution of the Patients (2015)
Table 15.22  Prevalence of Diabetes: Distribution by Continent (In Million)
Table 15.23  Treprostinil IV Formulation: Annual Sales, 2012 - Q1-Q3 2016 (USD Million)
Table 15.24  Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
Table 15.25  Herceptin®: Annual Sales, 1999-2015 (CHF Million)
Table 15.26 Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
Table 15.27  Apokyn®: Annual Sales, 2011-2015 (USD Million)
Table 15.28  Rocephin®: Annual Sales, 2014-2015 (CHF Million)
Table 15.29  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
Table 15.30  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, 2017-2027 (USD Million)
Table 15.31  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, 2017-2027 (USD Million)
Table 15.32  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
Table 15.33  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, Number of Units, 2017-2027 (Million)
Table 15.34  Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, Number of Units, 2017-2027 (Million)
Table 15.35  Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
Table 15.36  Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
Table 15.37  Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
Table 15.38  Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
Table 15.39  Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
Table 15.40  Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
Table 15.41  Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
Table 15.42  Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
Table 15.43  Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
Table 15.44  Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
Table 15.45  West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
Table 15.46  Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. 5AM Ventures
  2. Abbott Laboratories
  3. AbbVie
  4. AbGenomics
  5. Ablynx
  6. Acceleron Pharma
  7. Accord Healthcare
  8. Aduro Biotech
  9. Advaxis
  10. Agenus
  11. AgonOx
  12. Akorn
  13. Alder BioPharmaceuticals
  14. Alexion Pharmaceuticals
  15. Alixinox Pharmaceuticals
  16. Alnylam Pharmaceuticals
  17. AlphaCore Pharma
  18. Altor BioScience
  19. Alzheimer’s Association
  20. American Academy of Neurology
  21. American Nurses Association
  22. Amgen
  23. Amphastar Pharmaceuticals
  24. Animas Corporation
  25. Antares Pharma
  26. Antigen Express
  27. Apotex
  28. Arbutus Biopharma
  29. Argos Therapeutics
  30. Arteaus Therapeutics
  31. Arthurian Life Sciences
  32. ARTORG Center for Biomedical Research
  33. Asante Solutions
  34. Aspen Pharmacare
  35. Astellas Pharma
  36. Asthma and Allergy Foundation of America
  37. AstraZeneca
  38. Athersys
  39. Aurum Pharmaceuticals
  40. AVEO Oncology
  41. Banque
  42. Bardy Diagnostics
  43. Baxter
  44. Bayer
  45. Bayhill Therapeutics
  46. Becton Dickinson
  47. Bespak
  48. Bigfoot Biomedical
  49. BioArctic Neuroscience
  50. bioCSL
  51. Biogen
  52. BioInvent International
  53. Bioject Medical Technologies
  54. BioMarin Pharmaceutical
  55. Bio-Path Holdings
  56. Biotest
  57. Boehringer Ingelheim
  58. Bristol-Myers Squibb
  59. Cala Health
  60. Calando Pharmaceuticals
  61. Cam Med
  62. Canadian Institute for Health Information
  63. Canadian Intellectual Property Office
  64. Cancer Advances
  65. CANÈ
  66. Cardiome Pharma
  67. Catalyst Biosciences
  68. Celgene
  69. Celldex Therapeutics
  70. Cellerant Therapeutics
  71. Cellnovo
  72. CEL-SCI Corporation
  73. Centers for Disease Control and Prevention
  74. CeQur
  75. Chugai Pharmaceutical
  76. Cincinnati Children’s Hospital Medical Center
  77. Cipla
  78. Circadian Technologies
  79. Cleveland BioLabs
  80. CONNECT
  81. Consort Medical
  82. Crealta Pharmaceuticals
  83. CROSSJECT
  84. CSL Behring
  85. CureTech
  86. CytoDyn
  87. Cytonet
  88. Daikyo Seiko
  89. Debiotech
  90. Deerfield Management Company
  91. DEKA
  92. Dekkun
  93. Denderon
  94. Dexcom
  95. Diamyd Medical
  96. Diasend
  97. Bern University Hospital
  98. Duke University Medical Center
  99. Egalet Corporation
  100. Eisai
  101. Elan Pharmaceuticals
  102. Elcam Drug Delivery Devices
  103. Eli Lilly
  104. Elias Group
  105. Elusys Therapeutics
  106. Emcure Pharmaceuticals
  107. EMD Serono
  108. Emergent BioSolutions
  109. Emory University Hospital
  110. Enable Injections
  111. Endeavour Vision
  112. Endo Pharmaceuticals
  113. Endocyte
  114. Eternity Healthcare
  115. European Agency of Occupational Safety and Health
  116. European Pharma Group
  117. Federated Investors
  118. Ferring Pharmaceuticals
  119. FibroGen
  120. Finox Biotech
  121. Five Prime Therapeutics
  122. Flex (formerly Flextronix)
  123. Flowonix Medical
  124. Forma Medical Device Design
  125. Fresenius Kabi
  126. Galaxy Biotech
  127. Galena Biopharma
  128. Genentech
  129. Generon Corporation (Shanghai)
  130. Geno Pharmaceuticals
  131. Genzyme Corporation
  132. Gilead Sciences
  133. Gland Pharma
  134. GlaxoSmithKline
  135. Gliknik
  136. Glooko
  137. Halozyme Therapeutics
  138. HanAll BioPharma
  139. Hanmi Pharmaceutical
  140. HealthPrize Technologies
  141. Heart Failure Clinical Research Network
  142. Heart Failure Society of America
  143. Hemispherx Biopharma
  144. Hospira
  145. ImClone Systems
  146. Immatics Biotechnologies
  147. Immune Response BioPharma
  148. Immunocore
  149. ImmunoFrontier
  150. ImmunoGen
  151. Immunomedics
  152. Immunotope
  153. Immunovaccine
  154. Immunovative Therapies
  155. Ind-Swift
  156. Ingenus Pharmaceuticals
  157. INJEX Pharma
  158. Inovio Pharmaceuticals
  159. Insulet Corporation
  160. Insuline Medical
  161. International Diabetes Federation
  162. Ionis Pharmaceuticals
  163. IP Holdings
  164. Ipca Laboratories
  165. Ipsen
  166. iSense CGM
  167. Janssen Biotech
  168. Johnson & Johnson
  169. Kaléo
  170. KaloBios Pharmaceuticals
  171. KB Partners
  172. Kyowa Hakko Kirin
  173. Leading Pharma
  174. LifeScan
  175. Lundbeckfonden Ventures
  176. MabVax Therapeutics
  177. MacroGenics
  178. Massachusetts General Hospital
  179. Mayo Clinic
  180. MEDAXOR
  181. Medical International Technology
  182. Medicom Innovation Partner
  183. Medicus Engineering
  184. MedImmune
  185. Medimop Medical Projects
  186. Medipacs
  187. Medtronic
  188. Medtrum
  189. MENTRIK Biotech
  190. Merck
  191. Meridian Medical Technologies
  192. Merrimack Pharmaceuticals
  193. Merz Pharma
  194. MetroHealth System
  195. Mode AGC
  196. Modi Mundi Pharma
  197. MolMed
  198. MorphoSys
  199. Morphotek
  200. Mylan
  201. Bar Ilan University
  202. National Institute for Clinical Excellence
  203. National Institutes of Health
  204. Neogenix Oncology
  205. Neon Laboratories
  206. NeuroDerm
  207. Noble
  208. Norwich Pharmaceuticals
  209. Novartis
  210. Novo Nordisk
  211. Nuron Biotech
  212. Occupational Safety and Health Administration
  213. Octapharma
  214. Omeros
  215. OncoGenex Pharmaceuticals
  216. OncoMed Pharmaceuticals
  217. OncoPep
  218. Optimer Pharmaceuticals
  219. OrbiMed
  220. ORI Healthcare Fund
  221. Otsuka Pharmaceutical
  222. Owen Mumford
  223. Peregrine Pharmaceuticals
  224. Perqflo
  225. Pfizer
  226. PharmaJet
  227. PhaseBio Pharmaceuticals
  228. Pico Life Technologies
  229. PicoSulin
  230. Pique Therapeutics
  231. Pliva
  232. Pluristem Therapeutics
  233. Polaris Pharmaceuticals
  234. Polynoma
  235. Portola Pharmaceuticals
  236. Prachi Pharmaceuticals
  237. Progenics Pharmaceuticals
  238. Promethera Biosciences
  239. Prometheus Laboratories
  240. Protalix BioTherapeutics
  241. Qualitest Pharmaceuticals
  242. Quest Pharmatech
  243. Quintessence Biosciences
  244. RAD BioMed
  245. Ranbaxy Laboratories
  246. Ratio Drug Delivery
  247. Regeneron Pharmaceuticals
  248. rEVO Biologics
  249. Roche
  250. Roehr Products
  251. Roxane Laboratories
  252. Sagent Pharmaceuticals
  253. Salix Pharmaceuticals
  254. Samson Ventures Partners
  255. Sandoz
  256. Sangamo BioSciences
  257. Sanofi
  258. Sarpeta Therapeutics
  259. SBIR Healthcare
  260. Schroders
  261. SciGen
  262. scPharmaceuticals
  263. Seattle Genetics
  264. Sensile Medical
  265. Shionogi
  266. Shire
  267. Sigma-Tau Pharmaceuticals
  268. SillaJen BioTherapeutics
  269. SOOIL
  270. SteadyMed Therapeutics
  271. Stemline Therapeutics
  272. STMicroelectronics
  273. Sun Pharmaceutical Industries
  274. Sunovion Pharmaceuticals
  275. Syntax Corporation
  276. TaiMed Biologics
  277. Takeda Pharmaceutical Company
  278. Tamir Biotechnology
  279. Tandem Diabetes Care
  280. Teva Pharmaceutical Industries
  281. TG Therapeutics
  282. The Tech Group
  283. Tidepool
  284. Touche Medical
  285. TRACON Pharmaceuticals
  286. TypeZero Technologies
  287. UCB
  288. Unilife Corporation
  289. United Biomedical
  290. United States Patent and Trademark Office
  291. United Therapeutics
  292. University of Bern
  293. US WorldMeds
  294. Vaccinex
  295. Vaccinogen
  296. Valeritas
  297. Valtronic
  298. VBL Therapeutics
  299. VI Partners
  300. ViCentra
  301. Vintage Pharmaceuticals
  302. West Pharmaceutical Services
  303. Wockhardt
  304. Woodford Investment Management
  305. World Intellectual Property Organization
  306. XBiotech
  307. Xencor
  308. XOMA Corporation
  309. YOFimeter
  310. Ypsomed
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com